Inspire Medical Systems Inc

INSP sits in a Stage 2 advance with active Lockout Rally dynamics and mean-reversion eligibility, giving a bullish medium-term setup despite an overarching long-term downtrend. Short-term timing is favorable via the Lockout Rally override, allowing a Buy Now approach into continuation above rising EMAs. Key risks include overbought conditions and potential Stage 2→3 transition at structural highs.

• ↑100k+ patients treated – strong adoption in underserved OSA market
• ↑79.5% responder rate and 20% shorter surgical times in Inspire 5 trial
• ↓Coding and reimbursement uncertainty may trim $120–150 M of 2026 revenue